Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tiziana Life Sciences Ltd (TLSA : NSDQ)

• Company Description    Tiziana Life Sciences PLC is a biotechnology company. It focuses on the clinical development for the treatment of cancers, chronic inflammatory and autoimmune neurodegenerative disorders. The company's product pipeline consists of Foralumab TZLS-401 and Milciclib TZLS-201 which are in clinical stage. Tiziana Life Sciences PLC is based in London, United Kingdom. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $1.48 Daily Weekly Monthly 20 Day Moving Average: 187,164 shares Shares Outstanding: 116.85 (millions) Market Capitalization: $172.93 (millions) Beta: -0.05 52 Week High: $1.91 52 Week Low: $0.63 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.52% -8.83% 12 Week 38.32% 16.73% Year To Date 112.58% 99.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 14-15 CONDUIT STREET - LONDON,X0 W1S 2XJ GBR ph: 44-20-7495-2379 fax: - ikoffler@lifesciadvisors.com http://www.tizianalifesciences.com

• General Corporate Information    Officers Ivor Elrifi - Chief Executive Officer Gabriele Marco Antonio Cerrone - Executive Chairman Keeren Shah - Chief Financial Officer and Chief Operating Office Willy Simon - Director John Brancaccio - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G88912103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 116.85 Most Recent Split Date: 7.00 (2.50:1) Beta: -0.05 Market Capitalization: $172.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 39.63 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 1.02 Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - 1.02 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - 0.04 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - 0.00

Powered by Zacks Investment Research ©